Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

18 Aug 2020

1115.60

-0.32%

AUROBINDO PHARMA LTD

Buy: Aurobindo Pharma Ltd.

Target

Geojit BNP Paribas

We remain positive on the stock on account of healthy US formulation business growth, new products launches and strong pipeline. Separately, we believe smooth road ahead as company received EIR status for Hyderabad facility. Hence, we reiterate our BUY rating on the...

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

13 Aug 2020

1115.60

-0.32%

Aurobindo Pharma (BUY): In-line Q1; earnings, balance sheet comfort merit higher multiple

Buy: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q1 revenue/EBITDA were in line backed by strong US sales and sustained gross margins.

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1126.0

Aurobindo Pharma Ltd.

13 Aug 2020

1115.60

-0.32%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

US key growth driver despite recent compliance upheavals After filing its first ANDA in the US in 2003, the company has come a long way as current ANDA filings are at 604. US revenues have grown from ~US$100 million in 2009 crossing $1.6 billion sales as on 2020. In rupee terms, US sales have grown at 17% CAGR to | 11484 crore in FY16-20. US formulations now constitute 50% of total turnover, up from 30% in FY13. Despite calling off the acquisition of Sandoz' US dermatology and oral solid portfolio, we expect US revenue size to reach | 14925 crore in FY22E at a...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.9

Aurobindo Pharma Ltd.

13 Aug 2020

1115.60

-0.32%

Q1FY21 Result Update - Limited hope to surprise; Downgrade to Hold

Hold: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

1QFY21 earnings were in-line with our estimate with sequential decline in revenue and PAT of 4% and 8% respectively. We believe incremental growth would be challenging for US business due to regulatory issue and slowdown in AuroMedics portfolio caused by lower footfalls in hospital. Auromedics (17% of US sales in FY20) declined by 33% in last 2 quarters and outlook remains bleak. Despite FY21E guidance of 45-50 new launches in US, ARBP may lag behind as resolution over multiple plants remains elusive. ARBP also...

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

16 Jun 2020

1115.60

-0.32%

Monthly Update - IPM: Declining trend maintains on extended lockdown

Accumulate: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

Price fix of 40 formulations by NPPA will not have an impact on listed entities. With the disruption in productions, logistical movement and manpower scarcity, IPM growth declined in first two months of FY21E. The severity of declining trend is visible in 1) acute-heavy portfolios, 2) top premium brands (with alternative cheaper/generic drugs), 3) drugs used in hospital surgeries, 4) secondary therapies like Derma, Opthal, vaccines, stimulants and hormones whose treatment can be delayed. Key listed companies such as Alkem, GlaxoSmithKline, Alembic, FDC, Indoco are to be impacted in...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.9

Aurobindo Pharma Ltd.

05 Jun 2020

1115.60

-0.32%

Q4FY20 Result Update - Operationally strong led by EM/Europe/ARV - Accumulate

Accumulate: Aurobindo Pharma Ltd.

Recommendation Target

Prabhudas Lilladhar

We believe regulatory issues are likely to abate in FY21E as CAPA (Corrective and Preventive Actions) have been completed for Unit-I, IX, VII, and XI and ARBP is in continuous discussion with FDA for virtual cGMP audit. We believe successful resolution will lead ARBP to launch 50-60 quality products in FY21E with better realization due to favorable forex. ARBP had received only 22 ANDAs approval in FY20 versus 49 in FY19 and 51 in FY18. The lower approval was on the back of regulatory issues in its two key plants...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.9

Aurobindo Pharma Ltd.

04 Jun 2020

1115.60

-0.32%

Better traction in US, EU; superior product mix drives earnings

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

4 June 2020 Despite slowdown in ANDA approvals due to regulatory hurdles, ARBP delivered better-than-expected earnings on increased market share in existing products. With the VAI classification at Unit-4 and an increasing number of filings from sites under successful compliance, we expect the pace of launches to improve in the US market going forward. Turnaround in Apotex and continuous effort to better margins in the EU business would further boost overall profitability. The API business (12% of sales) was down 17.6% YoY, which dragged down overall growth to some extent. higher other expenses / employee cost (+240bp YoY /+50bp YoY as a percentage of sales), offset by lower R&D; spend (-50bp YoY as a percentage ARBP saw forex loss of INR260m and exceptional cost of INR120m related to 29.7% on revenue growth, better operating margins, and a lower tax rate.

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

04 Jun 2020

1115.60

-0.32%

Aurobindo Pharma (BUY): Strong Q4; upside risk to EPS can support higher multiple

Buy: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA beat estimates by 2%/9% led by strong sales (ex-US) and gross margin expansion.

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

04 Jun 2020

1115.60

-0.32%

Aurobindo Pharm

Hold: Aurobindo Pharma Ltd.

Recommendation Target

Sharekhan

Aurobindo Pharma Limited's (Aurobindo's) results for Q4FY2020 were better than estimates. Sales grew in double digits, by 16.4% to Rs. 6,158 crore because of sturdy 23% y-o-y growth in the formulations business. Double-digit growth across all regions drove the formulations segment's revenues. The API segment reported a drop of 17.6% y-o-y. Operating margins at 21.8% expanded by 180 bps y-o-y led by a sharp expansion in gross margins, attributable to favorable mix and benefits of low costs raw material inventory. Operating profit, at Rs. 1,342 crore grew by 26.6% y-o-y. Adjusting for one-offs, PAT stood at Rs 882 crore, rising 41% y-o-y...

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

21 Apr 2020, 12:00AM

1115.60

-0.32%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Whilst four plants continuing to be under USFDA scrutiny [Unit XI has warning letter, Unit VII, Unit I, Unit IX have official action indicated (OAI) status from the USFDA], re-assignment of VAI status for Unit IV despite 14 observations (that too for an injectable plant where cGMP requirements are even more stringent) came in as a huge positive surprise to us. Unit IV is a critical plant for the company, given most of its pending injectables are filed from this plant. Injectable segment is one of the key drivers for the company's future growth and margins. We expect the US injectable...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1126.0

Is Aurobindo Pharma Ltd. worth buying?

1257 Votes:

Buy 80.27%

Sell 13.76%

Hold 5.97%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf